Celera's Q4 Revenues Increase 15 Percent; Swings to Loss
February 18, 2009
Celera's Q4 Revenues Increase 15 Percent; Swings to Loss
Celera's revenues were driven by sales of its KIF6 testing service, but the firm posted a loss for the second quarter in a row on higher SG&A spending related to building its infrastructure following its split from Applera.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter - Medco Study Suggests Genetic Testing Improves Patient Compliance with Statins
October 19, 2011 / Pharmacogenomics Reporter - Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
April 15, 2011 / ProteoMonitor - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - Celera and Medco Join Forces to Study Statin Adherence Following KIF6 Testing
September 23, 2009 / Pharmacogenomics Reporter